RU2019116018A3 - - Google Patents

Download PDF

Info

Publication number
RU2019116018A3
RU2019116018A3 RU2019116018A RU2019116018A RU2019116018A3 RU 2019116018 A3 RU2019116018 A3 RU 2019116018A3 RU 2019116018 A RU2019116018 A RU 2019116018A RU 2019116018 A RU2019116018 A RU 2019116018A RU 2019116018 A3 RU2019116018 A3 RU 2019116018A3
Authority
RU
Russia
Application number
RU2019116018A
Other versions
RU2786476C2 (ru
RU2019116018A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019116018A publication Critical patent/RU2019116018A/ru
Publication of RU2019116018A3 publication Critical patent/RU2019116018A3/ru
Application granted granted Critical
Publication of RU2786476C2 publication Critical patent/RU2786476C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019116018A 2016-10-27 2017-10-26 Композиция, содержащая антитело против протофибрилл абета и ингибитор бета-секретазы васе1 для лечения болезни альцгеймера RU2786476C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662413961P 2016-10-27 2016-10-27
US62/413,961 2016-10-27
US201662415165P 2016-10-31 2016-10-31
US62/415,165 2016-10-31
PCT/US2017/058587 WO2018081460A1 (en) 2016-10-27 2017-10-26 Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022133025A Division RU2022133025A (ru) 2016-10-27 2017-10-26 Композиция, содержащая антитело против протофибрилл абета и ингибитор бета-секретазы bace1 для лечения болезни альцгеймера

Publications (3)

Publication Number Publication Date
RU2019116018A RU2019116018A (ru) 2020-11-27
RU2019116018A3 true RU2019116018A3 (ru) 2021-02-05
RU2786476C2 RU2786476C2 (ru) 2022-12-21

Family

ID=

Also Published As

Publication number Publication date
AU2017347838B2 (en) 2023-04-27
SG11201903601QA (en) 2019-05-30
KR20240015733A (ko) 2024-02-05
CN117244056A (zh) 2023-12-19
SG10201913049QA (en) 2020-02-27
JP2023139116A (ja) 2023-10-03
WO2018081460A1 (en) 2018-05-03
CA3042020A1 (en) 2018-05-03
AU2017347838A1 (en) 2019-06-13
EP3532485A1 (en) 2019-09-04
US20200299411A9 (en) 2020-09-24
JP2022092013A (ja) 2022-06-21
JP2020500165A (ja) 2020-01-09
JP7319421B2 (ja) 2023-08-01
MX2019004872A (es) 2019-10-30
US20230146896A1 (en) 2023-05-11
AU2023208107A1 (en) 2023-08-17
CN110214146A (zh) 2019-09-06
US20190276560A1 (en) 2019-09-12
KR102630042B1 (ko) 2024-01-29
CN110214146B (zh) 2023-08-29
IL266114A (en) 2019-06-30
BR112019008359A2 (pt) 2019-10-01
KR20190102181A (ko) 2019-09-03
JP7116725B2 (ja) 2022-08-10
RU2019116018A (ru) 2020-11-27

Similar Documents

Publication Publication Date Title
RU2019116018A3 (ru)
JP1585162S (ru)
JP1578943S (ru)
CN303770316S (ru)
CN303604000S (ru)
CN303611825S (ru)
CN303610220S (ru)
CN303607976S (ru)
CN303607189S (ru)
CN303606875S (ru)
CN303589218S (ru)
CN303597857S (ru)
CN303584847S (ru)
CN303597846S (ru)
CN303597153S (ru)
CN303579876S (ru)
CN303591093S (ru)
CN303589969S (ru)
CN303582961S (ru)
CN303580832S (ru)
CN303575785S (ru)
CN303575784S (ru)
CN303574178S (ru)
CN303572654S (ru)
CN303570598S (ru)